Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists
U Schilling, J Dingemanse, M Ufer - Clinical Pharmacokinetics, 2020 - Springer
Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …
The role of CYP450 drug metabolism in precision cardio-oncology
OA Fatunde, SA Brown - International journal of molecular sciences, 2020 - mdpi.com
As many novel cancer therapies continue to emerge, the field of Cardio-Oncology (or onco-
cardiology) has become crucial to prevent, monitor and treat cancer therapy-related …
cardiology) has become crucial to prevent, monitor and treat cancer therapy-related …
Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention …
EJ Dayoub, M Seigerman, S Tuteja… - JAMA internal …, 2018 - jamanetwork.com
Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor
hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) …
hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) …
Rates of intracranial hemorrhage in mild head trauma patients presenting to emergency department and their management: a comparison of direct oral anticoagulant …
G Savioli, IF Ceresa, S Luzzi, C Gragnaniello… - Medicina, 2020 - mdpi.com
Background and objectives: Anticoagulants are thought to increase the risks of traumatic
intracranial injury and poor clinical outcomes after blunt head trauma. The safety of using …
intracranial injury and poor clinical outcomes after blunt head trauma. The safety of using …
Prevalence of intracranial injury in adult patients with blunt head trauma with and without anticoagulant or antiplatelet use
MA Probst, M Gupta, GW Hendey… - Annals of emergency …, 2020 - Elsevier
Study objective We determine the prevalence of significant intracranial injury among adults
with blunt head trauma who are receiving preinjury anticoagulant or antiplatelet …
with blunt head trauma who are receiving preinjury anticoagulant or antiplatelet …
[HTML][HTML] Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention
Objective To evaluate the cost-effectiveness of multigene testing (CYP2C19, SLCO1B1,
CYP2C9, VKORC1) compared with single-gene testing (CYP2C19) and standard of care (no …
CYP2C9, VKORC1) compared with single-gene testing (CYP2C19) and standard of care (no …
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
Background: The P2Y12 receptor antagonist selatogrel is being developed for
subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute …
subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute …
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical …
Background and objectives We sought to determine the frequency of use and association
between prasugrel and outcomes in acute coronary syndrome patients undergoing …
between prasugrel and outcomes in acute coronary syndrome patients undergoing …
Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US
Importance A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy
for patients undergoing percutaneous coronary intervention (PCI) for acute coronary …
for patients undergoing percutaneous coronary intervention (PCI) for acute coronary …
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000–2016
N Farhat, N Haddad, J Crispo, N Birkett… - European Journal of …, 2019 - Springer
Abstract Purpose The US Food and Drug Administration (FDA) issued three safety
announcements between January 2009 and October 2010 warning against concomitant use …
announcements between January 2009 and October 2010 warning against concomitant use …